Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216782 | 0.84 | AHR (0.47) | AHRALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL6166378 | 0.81 | AHR (0.53) | AHRALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL5219139 | 0.78 | MIF (0.48) | AHRALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL5215762 | 0.77 | AHR (0.49) | AHRALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL5221390 | 0.77 | MIF (0.47) | AHRALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL5215869 | 0.77 | AHR (0.48) | AHRALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL5220309 | 0.76 | DHODH (0.49) | AHRALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL5220954 | 0.76 | KMT2A (0.54) | ALDH1A1KDM4EMIFGRM2MEN1 | |
| SCHEMBL5220905 | 0.76 | AHR (0.47) | AHRALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL5216628 | 0.76 | AHR (0.47) | AHRALDH1A1MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100387594-C | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2008-05-14 | — | — | CN | claimed |
| EP-1458383-B1 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | claimed |
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. | 2006-08-31 | — | — | US | claimed |
| CN-1795184-A | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2006-06-28 | — | — | CN | claimed |
| EP-1613614-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050026963-A1 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME LLC | 2005-02-03 | — | — | US | claimed |
| WO-2004089303-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | claimed |
| US-7569592-B2 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569592-B2 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026963-A1 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN2C | AHR 613/4885ALDH1A1 2988/4885MAPT 2547/4885 |
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRM1, GRIK5 | AHR 533/4885ALDH1A1 670/4885MAPT 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.